Published in Proc Natl Acad Sci U S A on December 19, 2005
Gene-engineered T cells for cancer therapy. Nat Rev Cancer (2013) 2.07
Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev (2014) 1.81
Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions. J Gene Med (2012) 1.40
Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol Ther (2013) 1.33
Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells. Immunol Rev (2014) 1.33
Chimeric antigen receptor-engineered T cells for immunotherapy of cancer. J Biomed Biotechnol (2010) 1.30
Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Expert Opin Biol Ther (2011) 1.27
Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells. Cancer Immunol Res (2015) 1.17
Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy. J Natl Cancer Inst (2016) 1.11
Clinical application of genetically modified T cells in cancer therapy. Clin Transl Immunology (2014) 1.03
Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen. Clin Cancer Res (2010) 1.02
Lewis y antigen promotes the proliferation of ovarian carcinoma-derived RMG-I cells through the PI3K/Akt signaling pathway. J Exp Clin Cancer Res (2009) 1.00
Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T Cells. Front Immunol (2013) 0.98
Mathematical modeling of chimeric TCR triggering predicts the magnitude of target lysis and its impairment by TCR downmodulation. J Immunol (2010) 0.89
Past, present and future targets for immunotherapy in ovarian cancer. Immunotherapy (2014) 0.87
Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells. ISRN Oncol (2012) 0.84
Preparing clinical grade Ag-specific T cells for adoptive immunotherapy trials. Cytotherapy (2007) 0.84
Manufacture of T cells using the Sleeping Beauty system to enforce expression of a CD19-specific chimeric antigen receptor. Cancer Gene Ther (2015) 0.83
Humanized Lewis-Y specific antibody based delivery of STAT3 siRNA. ACS Chem Biol (2011) 0.81
CAR T Cell Therapy: A Game Changer in Cancer Treatment. J Immunol Res (2016) 0.81
Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects. Mol Cancer (2014) 0.80
Developmental heterogeneity in DNA packaging patterns influences T-cell activation and transmigration. PLoS One (2012) 0.78
Engineered T cells for cancer treatment. Cytotherapy (2013) 0.78
Adoptive immunotherapy of cancer: Gene transfer of T cell specificity. Self Nonself (2011) 0.78
An Optimized GD2-Targeting Retroviral Cassette for More Potent and Safer Cellular Therapy of Neuroblastoma and Other Cancers. PLoS One (2016) 0.77
Adoptive T-cell therapy for Leukemia. Mol Cell Ther (2014) 0.77
Therapeutic targeting of Lewis(y) and Lewis(b) with a novel monoclonal antibody 692/29. PLoS One (2013) 0.76
Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. J Clin Invest (2017) 0.76
Manipulating the Lewis antigen specificity of the cholesterol-dependent cytolysin lectinolysin. Front Immunol (2012) 0.76
Engineering cell-based therapies to interface robustly with host physiology. Adv Drug Deliv Rev (2016) 0.75
Recent Developments in Cellular Immunotherapy for HSCT-Associated Complications. Front Immunol (2016) 0.75
Antibodies: At The Nexus of Antigens and Cancer Vaccines. J Infect Dis (2015) 0.75
Harnessing the immune response to target tumors. F1000Res (2017) 0.75
CAR-T cell therapy in ovarian cancer: from the bench to the bedside. Oncotarget (2017) 0.75
Adoptive T-Cell Therapy for Solid Tumors. Am Soc Clin Oncol Educ Book (2017) 0.75
Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61
Progress in human tumour immunology and immunotherapy. Nature (2001) 6.97
Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat Biotechnol (2002) 5.49
Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A (1993) 5.23
Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer (2003) 4.99
Transforming growth factor-beta in T-cell biology. Nat Rev Immunol (2002) 4.50
T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood (2002) 3.57
Correlation of expression of H/Le(y)/Le(b) antigens with survival in patients with carcinoma of the lung. N Engl J Med (1992) 2.52
Cytokines in cancer immunity and immunotherapy. Immunol Rev (2004) 2.09
Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood (2002) 1.98
Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther (2002) 1.96
Dual-specific T cells combine proliferation and antitumor activity. Nat Biotechnol (2002) 1.92
Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood (2002) 1.83
In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res (1995) 1.76
Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens. Int J Cancer (1997) 1.62
Genetic modification of T lymphocytes for adoptive immunotherapy. Mol Ther (2004) 1.41
Monoclonal antibody therapy for cancer. Annu Rev Med (2001) 1.39
Expression of Lewisa, Lewisb, X, and Y blood group antigens in human colonic tumors and normal tissue and in human tumor-derived cell lines. Cancer Res (1986) 1.36
Characterization of monoclonal antibodies B1 and B3 that react with mucinous adenocarcinomas. Cancer Res (1991) 1.34
Serological and immunochemical analysis of Lewis y (Ley) blood group antigen expression in epithelial ovarian cancer. Int J Cancer (1996) 1.33
Lewis blood group-related antigen expression in normal gastric epithelium, intestinal metaplasia, gastric adenoma, and gastric carcinoma. Am J Gastroenterol (1993) 1.33
Expression of LeY and extended LeY blood group-related antigens in human malignant, premalignant, and nonmalignant colonic tissues. Cancer Res (1986) 1.26
Functional balance between T cell chimeric receptor density and tumor associated antigen density: CTL mediated cytolysis and lymphokine production. Gene Ther (2000) 1.24
Activation-dependent expression of the blood group-related lewis Y antigen on peripheral blood granulocytes. J Leukoc Biol (2000) 1.14
Expansion and characterization of T cells transduced with a chimeric receptor against ovarian cancer. Hum Gene Ther (2000) 1.09
Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors. Cancer Res (2000) 1.06
Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy. Prostate (2004) 1.03
Primary polyclonal human T lymphocytes targeted to carcino-embryonic antigens and neural cell adhesion molecule tumor antigens by CD3zeta-based chimeric immune receptors. J Immunother (2002) 0.95
Structural convergence of antibody binding of carbohydrate determinants in Lewis Y tumor antigens. J Mol Biol (2004) 0.94
Immunotherapy of cancer using systemically delivered gene-modified human T lymphocytes. Hum Gene Ther (2004) 0.94
Construction, expression and characterisation of a single-chain diabody derived from a humanised anti-Lewis Y cancer targeting antibody using a heat-inducible bacterial secretion vector. Cancer Immunol Immunother (2001) 0.89
The fucosylated histo-blood group antigens H type 2 (blood group O, CD173) and Lewis Y (CD174) are expressed on CD34+ hematopoietic progenitors but absent on mature lymphocytes. Glycobiology (2001) 0.87
Immunohistochemical studies of blood group-related antigens in human superficial esophageal carcinomas. Cancer (1991) 0.86
Generation of anti-idiotype antibodies for application in clinical immunotherapy laboratory analyses. Hybrid Hybridomics (2003) 0.86
Expression of blood group-related antigens in cholangiocarcinoma in relation to non-neoplastic bile ducts. Histopathology (1996) 0.85
Expression of blood group-related antigens in normal and malignant pancreatic tissue correlated with genotype of the patient defined by saliva glycoprotein. Cancer (1993) 0.83
Correlation of prognosis of breast cancer patients and expression of Ley which acts as a cofactor of tumor procoagulant. Int J Oncol (1998) 0.81
Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes. Int J Cancer (1995) 0.81
Tissue-specific expression of Le(Y) antigen in high endothelial venules of human lymphoid tissues. Glycoconj J (1999) 0.77
Expression of Lewis Y (Le(y)) antigen in human anagen hair follicles. J Dermatol (1995) 0.77
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med (2007) 8.77
Adaptive immunity maintains occult cancer in an equilibrium state. Nature (2007) 8.14
NKT cells: what's in a name? Nat Rev Immunol (2004) 7.84
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature (2012) 7.76
Natural innate and adaptive immunity to cancer. Annu Rev Immunol (2011) 7.09
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med (2009) 6.73
Immune surveillance of tumors. J Clin Invest (2007) 5.04
IL-21 acts directly on B cells to regulate Bcl-6 expression and germinal center responses. J Exp Med (2010) 4.65
CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity. J Immunol (2006) 4.48
The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer (2008) 4.42
An immunosurveillance mechanism controls cancer cell ploidy. Science (2012) 4.35
DNA hypomethylation and human diseases. Biochim Biophys Acta (2006) 4.31
IL-21 regulates germinal center B cell differentiation and proliferation through a B cell-intrinsic mechanism. J Exp Med (2010) 4.04
Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol (2002) 3.96
Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity (2013) 3.73
A common fold mediates vertebrate defense and bacterial attack. Science (2007) 3.43
Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity (2013) 3.26
The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood (2010) 3.23
Functional interactions between dendritic cells and NK cells during viral infection. Nat Immunol (2002) 3.20
Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc Natl Acad Sci U S A (2008) 3.19
Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol (2009) 3.14
A natural killer T (NKT) cell developmental pathway iInvolving a thymus-dependent NK1.1(-)CD4(+) CD1d-dependent precursor stage. J Exp Med (2002) 3.13
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol (2009) 3.13
Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients. J Clin Oncol (2013) 3.04
Perforin-mediated target-cell death and immune homeostasis. Nat Rev Immunol (2006) 3.04
IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production. J Immunol (2007) 2.99
A network of PDZ-containing proteins regulates T cell polarity and morphology during migration and immunological synapse formation. Immunity (2005) 2.97
Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol (2012) 2.94
Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol (2002) 2.88
Differential antitumor immunity mediated by NKT cell subsets in vivo. J Exp Med (2005) 2.83
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci U S A (2004) 2.80
Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat Rev Immunol (2005) 2.77
A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J Exp Med (2002) 2.73
BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J Exp Med (2007) 2.70
Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci U S A (2010) 2.67
Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med (2012) 2.66
Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol (2012) 2.65
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood (2011) 2.64
Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res (2013) 2.62
Differential recognition of CD1d-alpha-galactosyl ceramide by the V beta 8.2 and V beta 7 semi-invariant NKT T cell receptors. Immunity (2009) 2.61
Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors. Cancer Res (2011) 2.59
Diverse cytokine production by NKT cell subsets and identification of an IL-17-producing CD4-NK1.1- NKT cell population. Proc Natl Acad Sci U S A (2008) 2.57
Membrane-bound Fas ligand only is essential for Fas-induced apoptosis. Nature (2009) 2.54
Glycolipid antigen drives rapid expansion and sustained cytokine production by NK T cells. J Immunol (2003) 2.48
Comparison of ultracentrifugation, density gradient separation, and immunoaffinity capture methods for isolating human colon cancer cell line LIM1863-derived exosomes. Methods (2012) 2.46
A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood (2008) 2.44
Differential development of murine dendritic cells by GM-CSF versus Flt3 ligand has implications for inflammation and trafficking. J Immunol (2007) 2.43
Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci U S A (2011) 2.35
A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J Exp Med (2005) 2.32
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest (2013) 2.30
NK cell maturation and peripheral homeostasis is associated with KLRG1 up-regulation. J Immunol (2007) 2.26
The structural basis for membrane binding and pore formation by lymphocyte perforin. Nature (2010) 2.23
Presumed guilty: natural killer T cell defects and human disease. Nat Rev Immunol (2011) 2.21
Cutting edge: IL-21 is not essential for Th17 differentiation or experimental autoimmune encephalomyelitis. J Immunol (2008) 2.19
The MACPF/CDC family of pore-forming toxins. Cell Microbiol (2008) 2.15
Eradication of established tumors in mice by a combination antibody-based therapy. Nat Med (2006) 2.10
CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J Immunol (2006) 2.10
Cytokines in cancer immunity and immunotherapy. Immunol Rev (2004) 2.09
Supernatural T cells: genetic modification of T cells for cancer therapy. Nat Rev Immunol (2005) 2.08
Gene-engineered T cells for cancer therapy. Nat Rev Cancer (2013) 2.07
Innate immunity defines the capacity of antiviral T cells to limit persistent infection. J Exp Med (2010) 2.06
Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med (2011) 2.04
CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res (2011) 2.03
IL-21 induces the functional maturation of murine NK cells. J Immunol (2004) 2.00
DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J Exp Med (2008) 2.00
The molecular basis for perforin oligomerization and transmembrane pore assembly. Immunity (2009) 1.98
Interleukin 15-mediated survival of natural killer cells is determined by interactions among Bim, Noxa and Mcl-1. Nat Immunol (2007) 1.97
Functional subsets of mouse natural killer cells. Immunol Rev (2006) 1.95
Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer. J Clin Oncol (2012) 1.95
Chemotherapy and radiotherapy: cryptic anticancer vaccines. Semin Immunol (2010) 1.94
Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res (2008) 1.94
Cancer immunoediting by the innate immune system in the absence of adaptive immunity. J Exp Med (2012) 1.93
Cytomegalovirus DNAemia and disease: incidence, natural history and management in settings other than allogeneic stem cell transplantation. Haematologica (2005) 1.92
Type I natural killer T cells suppress tumors caused by p53 loss in mice. Blood (2009) 1.91
Erdheim-Chester disease harboring the BRAF V600E mutation. J Clin Oncol (2012) 1.90
Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med (2002) 1.88
Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res (2011) 1.88
Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J Exp Med (2002) 1.85
Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J Immunol (2007) 1.84
Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood (2002) 1.83